Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 5, 2015-03 ,pp. : 409-418

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient Preferences for First-Line Oral Treatment for Mild-to-Moderate Ulcerative Colitis: A Discrete-Choice Experiment

By Hodgkins Paul  

The Patient: Patient-Centered Outcomes Research, Vol. 5, Iss. 1, 2012-03 ,pp. : 33-44

Adis International

Access to resources Recommend Favorite

Randomized Controlled Clinical Trials in Mild-Moderate Ulcerative Colitis

By  

Reviews on Recent Clinical Trials, Vol. 7, Iss. 4, 2012-11 ,pp. : 256-269

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial: tofacitinib and biologics for moderate‐to‐severe ulcerative colitis—what is best in class?

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 539-540

John Wiley & Sons Inc

Access to resources Recommend Favorite

Non-Pulmonary Effects Induced by the Addition of Formoterol to Budesonide Therapy in Patients with Mild or Moderate Persistent Asthma

By  

Respiration, Vol. 67, Iss. 1, 2000-02 ,pp. : 60-64

Karger

Access to resources Recommend Favorite